Last Price
0.37
Today's Change
-0.01 (2.63%)
Day's Change
0.366 - 0.389
Trading Volume
93,937
Market Cap
3 Million
Shares Outstanding
9 Million
Avg Volume
5,903,953
Avg Price (50 Days)
0.42
Avg Price (200 Days)
3.86
PE Ratio
-0.01
EPS
-35.64
Earnings Announcement
12-Nov-2024
Previous Close
0.38
Open
0.39
Day's Range
0.366 - 0.389
Year Range
0.285 - 21.648
Trading Volume
93,937
1 Day Change
-2.61%
5 Day Change
-6.49%
1 Month Change
-9.95%
3 Month Change
-49.23%
6 Month Change
-94.60%
Ytd Change
-95.27%
1 Year Change
-97.83%
3 Year Change
-99.95%
5 Year Change
-99.91%
10 Year Change
-99.99%
Max Change
-99.99%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.